Trial Outcomes & Findings for Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases (NCT NCT01944930)
NCT ID: NCT01944930
Last Updated: 2021-01-08
Results Overview
number of additionally visualized peritoneal lesions
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
23 participants
Primary outcome timeframe
After each Laparoscopy, at time of procedure
Results posted on
2021-01-08
Participant Flow
Participant milestones
| Measure |
Narrow Band Imaging Laparoscopy First
Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
Laparoscopic narrow band imaging
Standard white-light laparoscopy
|
Standard White-Light Laparoscopy First
Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
Laparoscopic narrow band imaging
Standard white-light laparoscopy
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
11
|
|
Overall Study
COMPLETED
|
10
|
10
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Baseline characteristics by cohort
| Measure |
Narrow Band Imaging Laparoscopy First
n=10 Participants
Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
Laparoscopic narrow band imaging
Standard white-light laparoscopy
|
Standard White-Light Laparoscopy First
n=10 Participants
Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
Laparoscopic narrow band imaging
Standard white-light laparoscopy
|
Total
n=20 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
10 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
70 years
STANDARD_DEVIATION 9 • n=5 Participants
|
56 years
STANDARD_DEVIATION 13 • n=7 Participants
|
63 years
STANDARD_DEVIATION 13 • n=5 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
10 participants
n=5 Participants
|
10 participants
n=7 Participants
|
20 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: After each Laparoscopy, at time of procedurenumber of additionally visualized peritoneal lesions
Outcome measures
| Measure |
Narrow Band Imaging Laparoscopy
n=20 Participants
Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
Laparoscopic narrow band imaging
|
Standard White-Light Laparoscopy
n=20 Participants
Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
Standard white-light laparoscopy
|
|---|---|---|
|
Rate of Detectable Peritoneal Metastases
|
0 percentage of lesions
|
2 percentage of lesions
|
Adverse Events
Narrow Band Imaging Laparoscopy First
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Standard White-Light Laparoscopy First
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place